Edition:
India

Pharmena SA (PHR.WA)

PHR.WA on Warsaw Stock Exchange

5.78PLN
24 Feb 2020
Change (% chg)

-0.10zł (-1.70%)
Prev Close
5.88zł
Open
5.40zł
Day's High
5.80zł
Day's Low
5.36zł
Volume
2,110
Avg. Vol
2,505
52-wk High
9.14zł
52-wk Low
4.81zł

Latest Key Developments (Source: Significant Developments)

Pharmena Starts Presentation Of Menavitin Diet Supplements
Monday, 20 Jan 2020 

Jan 20 (Reuters) - Pharmena SA ::STARTS PRESENTATION OF MENAVITIN DIET SUPPLEMENTS TO INDUSTRY TO FURTHER DEVELOP PROJECT IN EUROPE.  Full Article

Pharmena Q2 Net Loss Widens To 5.4 Mln Zlotys
Monday, 30 Sep 2019 

Sept 30 (Reuters) - Pharmena SA ::Q2 NET LOSS 5.4 MILLION ZLOTYS VERSUS LOSS OF 0.3 MILLION ZLOTYS YEAR AGO.Q2 REVENUE 2.1 MILLION ZLOTYS VERSUS 2.7 MILLION ZLOTYS YEAR AGO.  Full Article

Pharmena Starts Selling Its Products On Chinese T-Mall Internet Platform
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Pharmena SA ::SAYS STARTS SELLING ITS PRODUCTS ON CHINESE T-MALL INTERNET PLATFORM.  Full Article

Pharmena Introduces New Supplement, Menavitin Senior
Tuesday, 9 Jul 2019 

July 9 (Reuters) - Pharmena SA ::SAYS IS TO INTRODUCE NEW SUPPLEMENT, MENAVITIN SENIOR, FROM MENAVITIN LINE.  Full Article

Pharmena Q1 Net Result Turns To Loss Of 0.5 Mln Zlotys YoY
Thursday, 30 May 2019 

May 30 (Reuters) - Pharmena SA ::Q1 NET LOSS OF 0.5 MILLION ZLOTYS VERSUS PROFIT OF 0.7 MILLION ZLOTYS YEAR AGO.Q1 REVENUE 3.2 MILLION ZLOTYS VERSUS 3.7 MILLION ZLOTYS YEAR AGO.  Full Article

Pharmena Plans Pre-Clinical Test Of 1-MNA Drug On Animal Models
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Pharmena SA ::VIA ITS US-BASED UNIT CORTRIA CORPORATION PLANS TO LAUNCH PRE-CLINICAL TEST OF 1-MNA DRUG ON ANIMAL MODELS IN THE NASH INDICATION.PURPOSE OF PRE-CLINICAL TEST TO DETERMINE EFFECTIVE DOSAGE OF 1-MNA FOR FUTURE CLINICAL TESTS OF IIB PHASE.CO ESTIMATES TO PRESENT RESULTS FROM RESEARCH ON ANIMAL MODELS WITHIN ABOUT 6 MONTHS.  Full Article

Pharmena's Shares Start Trading On WSE Main Market As Of April 12
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Pharmena SA ::SAYS CO'S SHARES A,B C,D SERIES START TRADING ON MAIN MARKET AS OF APRIL 12.  Full Article

Pharmena Q3 Net Loss Narrows To 3,000 Zlotys
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - PHARMENA SA ::Q3 NET LOSS OF 3,000 ZLOTYS VERSUS LOSS OF 0.3 MILLION ZLOTYS YEAR AGO.Q3 REVENUE 3.1 MILLION ZLOTYS VERSUS 2.9 MILLION ZLOTYS YEAR AGO.  Full Article

Pharmena Plans To Launch Sales Of 1-MNA Dietary Supplements In Poland, Europe
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - PHARMENA SA ::PRESENTS ITS STRATEGY TO LAUNCH SALES OF 1-MNA DIET SUPPLEMENTS IN POLAND AND EUROPE.UNDER STRATEGY PLANS TO BUILD BRAND TO SELL SUPPLEMENTS, PHARMACIES TO BE MAIN DISTRIBUTION SOURCE IN POLAND.SAYS IN 2019-2023 PLANS TO ESTABLISH AT LEAST THREE UNITS RESPONSIBLE FOR SALES IN SPECIFIC COUNTRY OR PART OF EUROPE.ESTIMATES COSTS OF STRATEGY IMPLEMENTATION IN POLAND, EUROPE AT SEVERAL MILLION ZLOTYS.PLANS TO FINANCE STRATEGY THROUGH SERIES E SHARE ISSUE.SAYS HAS ANALYSED POSSIBILITY TO INTRODUCE 1-MNA DIETARY SUPPLEMENTS ON MARKETS OF CHINA, JAPAN, INDIA AND AUSTRALIA.  Full Article

Pharmena Proposes Share Capital Increase Of Up To 0.3 Mln Zlotys
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - PHARMENA SA ::SHAREHOLDERS ARE TO VOTE ON SEPT. 26 ON SHARE CAPITAL INCREASE OF UP TO 0.3 MILLION ZLOTYS.CAPITAL TO BE INCREASED VIA ISSUE OF UP TO 2.6 MILLION SERIES E SHARES IN CLOSED SUBSCRIPTION.  Full Article